Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Anti‐GD2 Antibody‐containing Immunotherapy Postconsolidation Therapy for People With High‐risk Neuroblastoma Treated With Autologous Haematopoietic Stem Cell Transplantation." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434652/1/images/ios-appstore-badge.png. Accessed 15 May 2024.
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/1/images/ios-appstore-badge.png. Accessed May 15, 2024.
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/1/images/ios-appstore-badge.png
Anti‐GD2 Antibody‐containing Immunotherapy Postconsolidation Therapy for People With High‐risk Neuroblastoma Treated With Autologous Haematopoietic Stem Cell Transplantation [Internet]. In: Cochrane Abstracts. [cited 2024 May 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/1/images/ios-appstore-badge.png.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
ID - 434652
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/1/images/ios-appstore-badge.png
DB - Evidence Central
DP - Unbound Medicine
ER -